MedTrace Logo

Swiss Postpartum Hypertension Cohort

NCT04690660 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2025-05-28

No results posted yet for this study

Summary

This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal risk.

Current disease management strategies will be evaluated.

Conditions

  • Postpartum Hypertension (PPHT)

Interventions

OTHER

Data collection for parameters of organ damage (cardiac and renal blood markers)

Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.

OTHER

Data collection for blood pressure (BP)

Clinic blood pressure and 24hour BP Measurements

OTHER

Home-based blood pressure management (substudy)

Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.

OTHER

Biomarker Profiles (substudy)

Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).

OTHER

Data collection on patient reported outcomes

Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Thenral Socrates, Dr. med. · Medical Outpatient Department and Hypertension Clinic, University Hospital BaselUni

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-04
Primary Completion
2030-05-31
Completion
2030-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04690660 on ClinicalTrials.gov